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Abstract
There is growing interest in applying machine learning methods for counterfactual
inference from observational data. However, approaches that account for survival
outcomes are relatively limited. Survival data are frequently encountered across
diverse medical applications, i.e., drug development, risk profiling, and clinical
trials, and such data are also relevant in fields like manufacturing (for equipment
monitoring). When the outcome of interest is time-to-event, special precautions
for handling censored events need to be taken, as ignoring censored outcomes may
lead to biased estimates. We propose a theoretically grounded unified framework
for counterfactual inference applicable to survival outcomes. Further, we formulate
a nonparametric hazard ratio metric for evaluating average and individualized
treatment effects. Experimental results on real-world and semi-synthetic datasets,
the latter which we introduce, demonstrate that the proposed approach significantly
outperforms competitive alternatives in both survival-outcome predictions and
treatment-effect estimation.
1 Introduction
Survival analysis or time-to-event studies focus on modeling the time of a future event, such as
death or failure, and investigate its relationship with covariates or predictors of interest. Specifically,
we may be interested in the causal effect of a given intervention or treatment on survival time. A
typical question may be: will a given therapy increase the chances of survival of an individual or
population? Such causal inquiries on survival outcomes are common in the fields of epidemiology
and medicine [15, 41]. As an important current example, the COVID-19 pandemic is creating a
demand for methodological development to address such questions, specifically, when evaluating the
effectiveness of a potential vaccine or medical treatments outside randomized controlled trial settings.
Traditional causal survival analysis is typically carried out in the context of a randomized controlled
trial (RCT), where the treatment assignment is controlled by researchers. Though they are the gold
standard for causal inference, RCTs are usually long-term engagements, expensive and limited in
sample size. Alternatively, the availability of observational data with comprehensive information
about patients, such as electronic health records (EHRs), constitutes a more accessible but also more
challenging source for estimating causal effects [17, 21]. Such observational data may be used to
augment and verify an RCT, after a particular treatment is approved and in use. Moreover, the
wealth of information from observational data also allows for the estimation of the individualized
treatment effect (ITE), namely, the causal effect of an intervention at the individual level. In this
work, we develop a novel framework to estimate the ITE for survival or time-to-event outcomes from
observational data.
Estimating the causal effect for survival outcomes in observational data manifests two principal
challenges. First, the treatment assignment mechanism is not known a priori. Therefore, there
may be variables, known as confounders, affecting both the treatment and survival time, which
lead to selection bias [3], i.e., that the distributions across treatment groups are not the same. For
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instance, patients who are severely ill are likely to receive more aggressive therapy, however, their
health status may also inevitably influence survival. Traditional survival analysis neglects such bias,
leading to incorrect causal estimation. Second, the exact time-to-event is not always observed, i.e.,
sometimes we only know that an event has not occurred up to a certain point in time. This is known
as the censoring problem. Further, censoring might be informative depending on the individuals’
characteristics, thus proper adjustment is required for accurate causal estimation.
Traditional causal survival-analysis approaches typically model the effect of the treatment or co-
variates (not time or survival) in a parametric manner. Two commonly used models are the Cox
proportional hazards (CoxPH) model [12] and the accelerated failure time (AFT) model [39], which
presume a parametric relationship between the covariates and survival probability. Further, proper
weighting for each individual has been employed to remove confounding bias from parametric models
[1, 2, 18]. Such parametric specification makes these models interpretable but compromises their
flexibility, and makes it difficult for them to be adapted for high-dimensional data or to capture
complex interactions among covariates. Fortunately, recent advances in machine learning, such as
representation learning or generative modeling, have enabled causal inference methods to handle high-
dimensional data and to characterize complex interactions effectively. For instance, there has been
recent interest in tree-based [11, 38] and neural-network-based [33, 42] approaches. When estimating
the ITE, some methods propose to regularize the transformed patient covariates or representations
to have balanced distributions across treatment groups, thus removing the confounding bias and
improving ITE prediction. However, most approaches employing machine learning techniques for
counterfactual inference deal with continuous or binary outcomes, instead of time-to-event outcomes.
Hence, a generalization to the context of survival analysis is needed.
To the best of our knowledge, this work constitutes the first attempt to leverage representation learning
to estimate ITE for survival outcomes in observational studies. We develop a framework to predict
event times from a low-dimensional (latent) transformation of the original covariate space. To address
the specific challenges associated with causal survival analysis, we make the following contributions:
• We develop an optimization objective incorporating proper adjustments for informative censoring,
as well as a balanced regularization term bounding the generalization error for ITE prediction. For
the latter, we repurpose a recently proposed bound [33] for our time-to-event scenario.
• We propose a generative model for event times, to relax restrictive survival parametric assumptions
and allow for more flexible modeling. Our approach can also provide nonparametric uncertainty
quantification for ITE predictions.
• We provide survival-specific evaluation metrics, including a new nonparametric hazard ratio
estimator, and discuss how to perform model selection for survival outcomes. The proposed model
demonstrates superior performance relative to the commonly used baselines in real-world and
semi-synthetic datasets.
• We introduce a survival-specific semi-synthetic dataset and demonstrate an approach for leveraging
prior randomized experiments in longitudinal studies for model validation.
2 Problem Formulation
We first introduce the basic setup for performing causal survival analysis in observational studies.
Suppose we have N units, with N1 units being treated and N0 in the control group (N = N1 +N0).
For each individual, we have covariates X , which can be heterogeneous, e.g., a mixture of categorical
and continuous covariates which, in the context of medicine, may include labs, vitals, procedure
codes, etc. We also have a treatment indicator A, where A = 0 for the controls and A = 1 for the
treated, as well as the outcome (event) of interest T . Under the potential outcomes framework [31], let
T0 and T1 be the potential event times for a given subject under control and treatment, respectively. In
practice we only observe one realization of the potential outcomes, i.e., the factual outcome T = TA,
while the counterfactual outcome T1−A is unobserved.
In the context of survival analysis, the problem becomes more difficult because we do not always
observe the exact event time for each individual, but rather the time up to which we are certain that
the event has not occurred; specifically, we have a (right) censoring problem, most likely due to the
loss of follow-up. We denote the censoring time as C and censoring indicator as δ ∈ {0, 1}. The
actual observed time is Y = min(TA, C), i.e., the outcome is observed (non-censored) if TA < C
and δ = 1.
2
(a) Counterfactual inference (b) Non-informative (c) Informative
Figure 1: (a) Illustration of the proposed Normalizing Flow Regression (NFR). Covariates X = x are
mapped into latent representation r via deterministic mapping r = Φ(x). The potential outcomes are
sampled from ta ∼ p(TA|X = x) for A = a via stochastic mapping hA(r, ˜), where randomness is
induced with a flow based transformation, ˜, of a simple distribution p(), i.e., uniform or Gaussian. (b)
and (c) show the proposed causal graphs for non-informative and informative censoring, respectively.
In this work, we are interested in the expected difference between the T1 and T0 given X for a
given unit (e.g., subject), which is commonly known as the individualized treatment effect (ITE).
Specifically, we wish to perform inference on the conditional distributions of T1 and T0, i.e., p(T1|X)
and p(T0|X), respectively, as shown in Figure 1(a). In practice, we observe N realizations of
(Y, δ,X,A) for observed time, censoring indicator, covariates and treatment indicator, respectively;
hence, from an observational study the dataset takes the form D = {(yi, δi, xi, ai)}Ni=1. Below, we
discuss several common choices of estimands in survival analysis.
2.1 Estimands of Interest
We begin by considering survival analysis in the absence of an intervening treatment choice, A. Let
F (t|x) , P (T ≤ t|X = x) be the cumulative distribution function of the event (failure) time, t,
given a realization of the covariates, x. Survival analysis is primarily concerned with characterization
of the survival function conditioned on covariates S(t|x) , 1 − F (t|x), and the hazard function
or risk score, λ(t|x), defined below. S(t|x) is a monotonically decreasing function indicating the
probability of survival up to time t. The hazard function measures the instantaneous probability of
the event occurring between {t, t+ ∆t} given T > t and ∆t→ 0. From standard survival function
definitions [24], the relationship between cumulative and hazard function is formulated as
λ(t|x) = lim
dt→0
P (t < T < t+ dt|X = x)
P (T > t|X = x)dt = −
d logS(t|x)
dt
=
f(t|x)
S(t|x) . (1)
From (1) we see that f(t|x) , P (T = t|X = x) = λ(t|x)S(t|x), is the the conditional event time
density function [24].
We now introduce the binary treatment A, and are interested in its impact on the survival time. For
ITE estimation, we are interested in the difference between the two potential outcomes T1, T0. Let
SA(t|x) and λA(t|x) denote the survival functions and hazard functions for the potential outcomes
TA, i.e., T1 and T0. Several common estimands of interest include [43, 36]:
• Difference in expected lifetime: ITE(x) = ∫ tmax
0
{S1(t|x)− S0(t|x)}dt = E{T1 − T0|X = x}.
• Difference in survival function: ITE(t, x) = S1(t|x)− S0(t|x).
• Hazard ratio: ITE(t, x) = λ1(t|x)/λ0(t|x).
The inference difficulties associated with the above estimands from observational data are two-fold.
First, there are confounders affecting both the treatment assignment and outcomes, which stem from
selection bias, i.e., the treatment and control covariate distributions are not necessarily the same.
Further, we do not have direct knowledge of the conditional treatment assignment mechanism, i.e.,
P (A = a|X = x), also known as the propensity score. Let⊥ denote statistical independence. For
estimands to be identifiable from observational data, we make two assumptions: (i) {T1, T0} ⊥ A|X ,
i.e., no unobserved confounders or ignorability, and (ii) overlap in the covariate support 0 < P (A =
1|X = x) < 1 almost surely if p(X = x) > 0. Second, the censoring mechanism is also unknown
and may lead to bias without proper adjustment. We consider two censoring mechanisms in our
work, (i) conditionally independent or informative censoring: T ⊥ C|X,A, and (ii) random or
non-informative censoring: T ⊥ C. Note that for informative censoring, we also have to consider
potential censoring times C1 and C0 and their conditionals p(C1|X) and p(C0|X), respectively.
Figure 1 shows causal graphs illustrating these modeling assumptions.
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3 Modeling
To overcome the above challenges and adjust for observational biases, we propose a unified frame-
work for counterfactual inference that accounts for survival outcomes. Specifically, we repurpose
the counterfactual bound in [33] for our time-to-event scenario and introduce a non-parametric
approach for survival outcome predictions based on normalizing flows [29]. Below we formulate
a theoretically grounded and unified approach for estimating (i) the encoder function r = Φ(x),
which deterministically maps covariates x to their corresponding latent representation r ∈ Rd, and
(ii) two stochastic time-to-event generative functions, hA(·), to implicitly draw samples from both
potential outcome conditionals ta ∼ ph,Φ(TA|X = x), for A = {1, 0}, and where ta indicates the
sample from ph,Φ(TA|X = x) is for A = a. Further, we formulate a general extension that accounts
for informative censoring by introducing two stochastic censoring generative functions, νA(·), to
draw samples for potential censoring times ca ∼ pν,Φ(CA|X = x). The model-specifying functions,
{hA(·), νA(·),Φ(·)}, are parameterized via neural networks. See the Supplementary Material (SM)
for details. Figure 1a summarizes our modeling approach.
3.1 Counterfactual Bound
We wish to estimate the treatment effect from intervention do(A = a) [28], where the potential
outcomes, event times, are sampled from distributions parameterized by functions {hA(·),Φ(·)}, i.e.,
t ∼ ph,Φ(T |X = x, do(A = a)) (2)
t ∼ ph,Φ(T |X = x,A = a) (3)
ta ∼ ph,Φ(TA|X = x), (4)
where (3) follows from (2) because identifiability holds, provided that X is a sufficient set from
A into T [28], consistent with the causal graphs in Figure 1b and 1c. We obtain (4) from (3) via
the strong ignorability assumption, i.e., {T0, T1} ⊥ A|X and 0 < P (A = a|X = x) < 1, and
the consistency assumption, i.e., T = TA|A = a. A similar argument can be made for informative
censoring based on Figure 1c, so we can also write ca ∼ pν,Φ(CA|X = x). Given (4), model
functions {hA(·),Φ(·)} and νA(·) for informative censoring can be learned by leveraging standard
statistical optimization approaches, that minimize a loss hypothesis L given samples from the
empirical distribution (y, δ, x, a) ∼ p(Y, δ,X,A), i.e., from dataset D. Specifically, we write L as
L = E(y,δ,x,a)∼p(Y,δ,X,A) [`h,Φ(ta, y, δ)] , (5)
where `h,Φ(ta, y, δ) is a loss function that measures the agreement of ta ∼ ph,Φ(TA|X = x) (and
ca ∼ pν,Φ(CA|X = x) for informative censoring) with ground truth {y, δ}, the observed time and
censoring indicator, respectively.
For some parametric formulations of event time distribution ph,Φ(TA|X = x), e.g., exponential,
Weibull, log-Normal, etc., and provided the censoring mechanism is non-informative, −`h,Φ(ta, y, δ)
is the closed-form log likelihood. Specifically, −`h,Φ(ta, y, δ) , log ph,Φ(Ta|X = x) = δ ·
log fh,Φ(ta|x) + (1− δ) · logSh,Φ(ta|x), which implies that the conditional event time density and
survival functions can be calculated in closed form from transformations {hA(·),Φ(·)} of x. See the
SM for parametric examples of (5) accounting for informative censoring.
We further define the expected loss for a given realization of covariates x and treatment assign-
ment a over observed times y (censored and non-censored), and the censoring indicator δ as
ζh,Φ(x, a) , E(y,δ,x)∼p(Y,δ|X)`h,Φ(ta, y, δ) as in [33]. For a given subject with covariates x and
treatment assignment a, we wish to minimize both the factual and counterfactual losses, LF and LCF,
respectively, by decomposing (5) into L = LF + LCF as follows
LF = E(x,a)∼p(A,X)ζh,Φ(x, a) , LCF = E(x,a)∼p(1−A,X)ζh,Φ(x, a) . (6)
Let u , P (A = 1) denote the marginal probability of treatment assignment. We can readily
decompose the losses in (6) according to treatment assignments. The decomposed factual LF =
u ·LA=1F +(1−u) ·LA=0F , and similarly, the decomposed counterfactual LCF = (1−u) ·LA=1CF +u ·
LA=0CF . In practice, only factual outcomes are observed, hence, for a non-randomized non-controlled
experiment, we cannot obtain an unbiased estimate of LCF from data due to selection bias (or
confounding). Therefore, we bound LCF and L below following [33].
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Corollary 1 Assume Φ(·) is an invertible map, and α−1ζh,Φ(x, a) ∈ G, where G is a family of
functions, pA=aΦ , pΦ(R|A = a) is the latent distribution for group A = a, and α > 0 is a constant.
Then, we have:
LCF ≤ (1− u) · LA=1F + u · LA=0F + α · IPMG(pA=1Φ , pA=0Φ )
L ≤ LA=1F + LA=0F + α · IPMG(pA=1Φ , pA=0Φ ) . (7)
The integral probability metric (IPM) [27, 35] measures the distance between two probability
distributions p and q defined over M , i.e., the latent space of R. Formally, IPMG(p, q) ,
supg∈G |
∫
M
g(m) (p(m)− q(m)) dm|, where g : m→ R, represents a class of real-valued bounded
measurable functions on M [33]. Therefore, model functions {ha(·),Φ(·)} can be learned by mini-
mizing the upper bound in (7) consisting of (i) only factual losses under both treatment assignments
and (ii) an IPM regularizer enforcing latent distributional equivalence between the treatment groups.
Note that if the data originates from a RCT it follows (by construction) that IPMG(pA=1Φ , p
A=0
Φ ) = 0.
3.2 Normalizing Flow Regression (NFR)
Below we formulate an approach for estimating functions hA(·) and νA(·) for synthesizing (sampling)
non-censored ta ∼ ph,Φ(TA|X = x) and censored ca ∼ pν,Φ(CA|X = x) times, respectively. While
some parametric assumptions for ph,Φ(TA|X = x) yield easy-to-evaluate closed forms for Sh,Φ(ta|x)
that can be used as likelihood for censored observations, they are restrictive, and have been shown to
generate unrealistic high variance samples [9]. So motivated, we seek a nonparametric likelihood-
based approach that can model a flexible family of distributions, with an easy to sample approach
for event times ta ∼ ph,Φ(Ta|X = x). Normalizing flows [29] have been applied successfully
to generative modeling due to their tractability and high sample quality [23]. Typically, a simple
distribution p(), i.e, Gaussian or uniform, is transformed via a sequence of invertible transformations
z = zL ◦ . . . z2 ◦ z1, into an arbitrarily complex distribution.
We conveniently model the event time generation process where the source of randomness is obtained
from an invertible planar flow parameterized by {Uh,Wh, bh} [29]. While we can apply L invert-
ible planar transformations for more complex structured distributions, empirically, we did not see
quantifiable performance benefits, therefore we model a single layer transformation as
˜h = + Uh tanh(Wh+ bh) ,  ∼ Uniform(0, 1) , ta = hA(r, ˜h) , r = Φ(x) (8)
where {Uh,Wh} ∈ Rd×d, {bh, } ∈ Rd, d is the dimensionality of the normalizing flow; each
component of  is drawn independently from Uniform(0, 1), and ˜h may be viewed as a skip
connection with stochastic in . Further, hA(r, ˜h) and Φ(x) are time-to-event generative and
encoding functions, respectively, parameterized as neural networks. For simplicity the dimensions of
r and  are set to d, however, they can be set independently if desired. In practice, we are interested
in generating realistic event-time samples; therefore, we account for both censored and non-censored
observations by adopting the objective from [9], formulated as
LNFRF , E(y,δ,x,a)∼p(Y,δ,X,A),∼p() [δ · (|y − ta|) + (1− δ) · (max(0, y − ta))] , (9)
where the first term encourages sampled event times ta to be close to y, the ground truth for observed
events, i.e., δ = 1, while penalizing ta for being smaller than the censoring time when δ = 0. Further,
the expectation is taken over samples (a minibatch) from empirical distribution p(Y, δ,X,A).
Informative censoring We model informative censoring similar to (9) but mirroring the censoring
indicators to encourage accurate censoring time samples ca for δ = 0, while penalizing ca for being
smaller than y for δ = 1 (observed events). Specifically, we set an independent planar flow like in (8)
but parameterized by {Uν ,Wν , bν} and censoring generative functions νA(r, ˜ν), parameterized as
neural networks, where ca ∼ pν,Φ(CA|X = x) formulated as
`c(ν,Φ) = E(y,δ,x,a)∼p(y,δ,X,A),∼p() [(1− δ) · (|y − ca|) + δ · (max(0, y − ca))] . (10)
Further, we introduce an additional time-order-consistency loss that enforces the correct order of the
observed time relative to the censoring indicator, i.e., ca < ta if δ = 0 and ta < ca if δ = 1, thus
`TC(h, ν,Φ) = E(δ,x,a)∼p(δ,X,A),∼p() [δ · (max(0, ta − ca)) + (1− δ) · (max(0, ca − ta))] (11)
Note that `TC(h, ν,Φ) does not depend on the observed event times but only on the censoring
indicators. Finally, we write the consolidated NFR-Informative censoring (NFR-INFO) loss by
aggregating (9), (10) and (11) as
LNFR−INFOF , LNFRF + `c + `TC . (12)
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Learning Model functions {hA(·),Φ(·), νA(·)} are learned by minimizing the bound (7), via
stochastic gradient descent on minibatches from D, with the factual loss (9) for non-informative
censoring (NFR) and (12) for informative censoring (NFR-INFO). Further, for the IPM regularization
loss in (7), we optimize the dual formulation of the Wasserstein distance, via the regularized optimal
transport [37, 14]. Consequently, we only require α−1ζh,Φ(x, a) to be 1-Lipschitz [33] and α is
selected by grid search on the validation set using only factual data (details below).
4 Metrics
We propose a comprehensive evaluation approach that accounts for both factual and causal metrics.
Factual survival outcome predictions are evaluated according to standard survival metrics that measure
diverse performance characteristics, such as concordance index (C-Index) [16], mean coefficient of
variation (COV) and calibration slope (C-slope) [8]. See the SM for more details on these metrics.
For causal metrics, defined below, we introduce a nonparametric hazard ratio (HR) between treatment
outcomes, and adopt the conventional precision in estimation of heterogeneous effect (PEHE) and
average treatment effect (ATE) performance metrics [19]. Note that PEHE and ATE require ground
truth counterfactual event times, which is only possible in (semi-)synthetic data. For HR, we compare
our findings with those independently reported in the literature from RCT data.
Nonparametric Hazard Ratio In a medical setting, the population hazard ratio HR(t) between
treatment groups is considered informative thus has been widely used in drug development and RCT
[41, 26]. For example, HR(t) < 1, > 1, or ≈ 1 indicate population positive, negative and neutral
treatment effects at time t, respectively. Moreover, HR(t) naturally accounts for both censored
and non-censored outcomes. Standard approaches for computing HR(t) rely on the restrictive
proportional hazard assumption from CoxPH [12], which is constituted as a semi-parametric linear
model λ(t|a) = λb(t) exp(aβ). However, the constant covariate (time independent) effect is often
violated in practice (see Figure 2b). For CoxPH, the marginal hazard ratio between treatment and
control can be obtained from regression coefficient β learned via maximum likelihood without the
need for specifying the baseline hazard λb(t):
HRCoxPH(t) =
λ(t|a = 1)
λ(t|a = 0) = exp(β) . (13)
So motivated, we propose a nonparametric, model-free approach for computing HR(t).
Definition 1 We define the nonparametric marginal Hazard Ratio and its approximation, HˆR(t), as
HR(t) =
λ1(t)
λ0(t)
=
S0(t)
S1(t)
· S
′
1(t)
S′0(t)
, HˆR(t) =
SˆPKM0 (t)
SˆPKM1 (t)
· m1(t)
m0(t)
, (14)
where for HR(t) we leveraged (1) and (13) to obtain (14) and S′(t) , dS(t)/dt. The nonparametric
assumption for S(t) makes the computation of S′(t) challenging. Provided that S(t) is a monotoni-
cally decreasing function, for simplicity, we fit a linear function S(t) = m · t+ c, and set S′(t) ≈ m.
Bias from S′(t) can be reduced by considering more complex function approximations for S(t),
e.g., polynomial or spline. Further, we leverage the model-free population point-estimate-based
nonparametric Kaplan-Meier [22] estimator of the survival function SˆPKM(t) in [8] to marginalize
both factual and counterfactual predictions given covariates x. The approximated hazard ratio, HˆR(t),
is thus obtained by combining the approximations SˆPKMa (t) and ma. See the SM for additional
details. A similar formulation for the conditional, HR(t|x), can also be derived. Note that for
some parametric formulations, HR(t|x), can be readily evaluated because f(ta|x) and S(ta|x) are
available in closed form.
Precision in Estimation of Heterogeneous Effect (PEHE) A general individualized estimation
error is formulated as PEHE =
√
EX [(ITE(x)− ˆITE(x))2], where ITE(x) is the ground truth,
ˆITE(x) = ET [γ (T1)− γ (T0) |X = x] and γ(·) is a deterministic transformation. In our experi-
ments, γ(·) is the average over samples from ta ∼ ph,Φ(TA|X = x). Alternative estimands, e.g.,
thresholding survival times γ(TA) = I{TA > τ}, can also be considered as described in Section 2.1.
Average Treatment Effect (ATE) The population treatment effect estimation error is defined as
ATE = |ATE− ˆATE|, where ATE = EX [ITE(x)] (ground truth) and ˆATE = EX [ ˆITE(x)].
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Table 1: Performance comparisons on ACTG-SYNTHETIC data, with 95% HR(t) confidence interval.
The ground truth, test set, hazard ratio is HR(t) = 0.52(0.39,0.71).
Method Causal Factual
PEHE ATE HR(t) C-Index (A=0, A=1) Mean COV C-Slope (A=0, A=1)
CoxPH-Uniform NA NA 0.97(0.86,1.09) NA NA NA
CoxPH-IPW NA NA 0.48(0.03,7.21) NA NA NA
CoxPH-OW NA NA 0.60(0.53,0.68) NA NA NA
Surv-BART 352.07 77.89 0.0(0.0, 0.0) (0.706, 0.686) 0.001 (0.398,∞)
AFT-Weibull 367.92 133.93 0.47(0.47,0.47) (0.21, 0.267) 6.209 (0.707, 0.729)
AFT-log-Normal 377.76 157.64 0.47(0.47,0.47) (0.675, 0.556) 6.971 (0.707, 0.729)
SR 369.47 88.55 0.38(0.33,0.65) (0.791, 0.744) 0 (0.985, 1.027)
NFR (proposed) 358.72 0.8 0.45(0.39,0.65) (0.787, 0.767) 0.131 (0.985, 1.026)
NFR-INFO (proposed) 344.3 31.19 0.53(0.41,0.67) (0.78, 0.764) 0.13 (0.999, 1.029)
5 Experiments
We describe the baselines and datasets that will be used to evaluate the proposed methods (NFR
and NFR-INFO). Pytorch code including the new semi-synthetic dataset (see below) will be made
publicly available. Throughout the experiments, we use HR(t) in (13) for CoxPH based methods
and (14) for all others. The bound in (7) is sensitive to α, thus we propose approximating proxy
counterfactual outcomes {YCF, δCF} for the validation set, according to the covariate Euclidean
nearest-neighbour (NN) from the training set. We select the α that minimizes the validation loss
L = LF + LCF from the set (0, 0.1, 1, 10, 100).
Baselines We consider the following competitive baseline approaches: (i) propensity weighted
CoxPH [32, 6, 30]; (ii) IPM (7) regularized AFT (log-Normal and Weibull) models; (iii) an IPM
(7) regularized deterministic semi-supervised regression (SR) model with accuracy objective from
[9], as a contrast for the proposed stochastic predictors (NFR and NFR-INFO); and (iv) survival
Bayesian additive regression trees (Surv-BART) [34]. For CoxPH, we consider three normalized
weighting schemes: (i) inverse probability weighting (IPW) [20, 7], where IPWi = aieˆi +
1−ai
1−eˆi ; ii)
overlapping weights (OW) [13, 25], where OWi = ai · (1− eˆi) + (1− ai) · eˆi; and iii) the standard
RCT uniform assumption. A simple linear logistic model eˆi = σ(xi;w), is used as an approximation,
eˆi, to the unknown propensity score P (A = 1|X = x). See the SM for a details of the baselines.
Table 2: Summary statistics of the datasets.
FRAMINGHAM ACTG ACTG-SYNTHETIC
Events (%) 26.0 26.9 48.9
Treatment (%) 10.4 49.5 55.9
N 3,435 1,054 2,139
p 32 23 23
Missing (%) 0.23 1.41 1.38
tmax (days) 7,279 1,231 1,313
Datasets We consider the following datasets: (i)
FRAMINGHAM, is an EHR-based longitudinal car-
diovascular cohort study that we use here to evaluate
the effect of statins on future coronary heart disease
outcomes [5]; (ii) ACTG, is a longitudinal RCT study
comparing monotherapy with Zidovudine or Didano-
sine with combination therapy in HIV patients [15];
and (iii) ACTG-SYNTHETIC, is a semi-synthetic dataset based on ACTG covariates. We simulate
potential outcomes according to a Gompertz-Cox distribution [4] with selection bias from a simple
logistic model for P (A = 1|X = x) and AFT-based censoring mechanism. The generative process
is detailed in the SM. Table 2 summarizes the datasets according to (i) covariates (continuous, one-
hot-encoded categorical) of size p; (ii) proportion of non-censored events, treated units, and missing
entries in the N × p covariate matrix; and (iii) time range tmax for both censored and non-censored
events. Missing entries are imputed with median or mode if continuous or categorical, respectively.
Quantitative Results Experimental results for two data-sets in Tables 1 and 3, illustrate that AFT-
based methods are high variance, inferior in calibration and C-Index than accuracy-based methods
(SR, NFR, NFR-INFO). Surv-BART is the least calibrated but low variance method. NFR-INFO and
NFR outperform all methods across all factual metrics, whereas NFR-INFO is better calibrated, low
variance but slightly lower C-Index than NFR. Note that we fit CoxPH using the entire dataset; since
it does not support counterfactual inference, we do not present factual metrics. By properly adjusting
for both informative censoring and selection bias, NFR-INFO significantly outperforms all methods
in treatment effect estimation according to HR(t) and PEHE, across non-RCT datasets, while
remaining comparable to AFT-Weibull on the RCT dataset (see the SM). Further, RCT-based results
on ACTG data in the SM illustrate comparable HR(t) across all models except for AFT-log-Normal
and Surv-BART, which overestimate, and SR, which underestimates risk. For non-RCT datasets
(ACTG-SYNTHENTIC and FRAMINGHAM), CoxPH-OW has a clear advantage over all CoxPH based
methods, mostly credited to the well-behaved bounded propensity weights ∈ [0, 1]. Interestingly, the
FRAMINGHAM observational data exhibits a common paradox, where without proper adjustment of
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Table 3: Performance comparisons on FRAMINGHAM data, with 95% HR(t) confidence interval.
Test set NN assignment of yCF and δCF yields biased HR(t) = 1.23(1.17,1.25), while previous large
scale longitudinal RCT studies estimated HR(t) = 0.75(0.64,0.88) [41].
Method Causal Factual
HR(t) C-Index (A=0, A=1) Mean COV C-Slope (A=0, A=1)
CoxPH-Uniform 1.69(1.38,2.07) NA NA NA
CoxPH-IPW 1.09(0.76,1.57) NA NA NA
CoxPH-OW 0.88(0.73,1.08) NA NA NA
Surv-BART 14.99(14.9,14.9e8) (0.629, 0.630) 0.003 (0.232, 0.084)
AFT-Weibull 1.09(1.09,1.09) (0.734, 0.395) 8.609 (0.857, 0.89)
AFT-log-Normal 1.55(1.46,1.55) (0.68, 0.56) 10.415 (0.979, 0.732)
SR 0.58(0.53,0.71) (0.601, 0.57) 0 (0.491, 0.63)
NFR (proposed) 1.04(1.00,1.09) (0.763, 0.728) 0.161 (0.891, 0.81)
NFR-INFO (proposed) 0.81(0.77,0.83) (0.752, 0.651) 0.156 (0.907, 0.881)
selection and censoring bias, naive approaches would result in a counter-intuitive treatment effect
from statins. However, there is severe confounding from covariates such as age, body mass index,
diabetes, history of peripheral artery disease (PAD), history of myocardial infarction (MI), history
of stroke, etc., that influence both treatment likelihood and survival time. Table 3, demonstrates
that NFR-INFO is clearly the best performing approach. Specifically, its HR(t), reverses the biased
observational treatment effect, to demonstrate positive treatment from statins, which is consistent
with prior large RCT longitudinal findings [41].
(a) ACTG-SYNTHENTIC HR(t) (b) FRAMINGHAM log HR(t|x) (c) FRAMINGHAM log HR(t|x) pdf
Figure 2: (a) Inferred population HR(t) compared against ground truth (EMP) on ACTG-SYNTHETIC
data. NFR-INFO-based (b) cluster-specific average log HR(t|x) curves and (c) estimated density of
median log HR(t|x) values on the test set of the FRAMINGHAM dataset. Clusters assignment were
obtained via hierarchical clustering of individualized log HR(t|x) traces.
Qualitative Results Figure 2a demonstrates that NFR-INFO matches the ground truth population
hazard, HR(t), better than alternative methods on ACTG-SYNTHETIC data. See the SM for ACTG
and FRAMINGHAM. Figure 2b shows sub-population log hazard ratios for four patient clusters
obtained via hierarchical clustering on the individual log hazard ratios, log HR(t|x), of the test set of
FRAMINGHAM data. Interestingly, these clusters stratify treatment effects into: positive (2), negative
(1 and 3), and neutral (4) sub-populations. Moreover, the estimated density of median log HR(t|x)
values in Figure 2c illustrates that nearly 70% of the testing set individuals have log HR(t|x) < 0,
thus may benefit from taking statins. Further, we isolated the extreme top and bottom quantiles,
HR(t|x) < 0.024 and HR(t|x) > 1.916, respectively, of the median log HR(t|x) values for the
test set of FRAMINGHAM, as shown in Figure 2c. After comparing their covariates, we found that
individuals with the following characteristics may benefit from taking statins: young, male, diabetic,
without prior history (cardiovascular disease, PAD, stroke or MI), high body max index, cholesterol,
triglycerides, fasting glucose, and low high-density lipoprotein. Note that individuals with contrasting
covariates experience adverse effects from taking statins. There seem to be consensus that diabetics
and high-cholesterol patients benefit from statins [10, 40]. See the SM for more qualitative results.
6 Conclusions
We have proposed the first unified counterfactual inference framework for survival analysis. Our
approach adjusts for bias from two unknown sources, namely, confounding due to covariate dependent
selection bias and censoring mechanism (informative or non-informative). We demonstrate superior
performance in both survival outcome predictions and treatment effect estimations than competitive
alternatives across three diverse datasets, including a semi-synthetic dataset which we introduce.
Moreover, we formulate a model-free nonparametric hazard ratio metric for comparing treatments
effects or leveraging prior randomized real-world experiments in longitudinal studies.
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Broader Impact
We proposed a unified framework for individualized treatment effect estimation for survival outcomes
from observation data. Our approach is an inexpensive alternative to time consuming RCTs, albeit,
requires proper adjustment of biases due to confounding and censoring. Though we tailored our
study to medical applications, i.e., drug development, risk profiling, clinical trials, etc., we believe
the framework is general and can be extended to other applications that characterize the future event
time given covariates. It is our intent to encourage researchers in the survival analysis and causal
inference communities to consider the problem of counterfactual inference for survival outcomes.
Additionally, our proposed method can be used for social good by adjusting for selection bias and
censoring in high stake decision making, i.e, financial, healthcare, recidivism risk profiling. We hope
our end users will use this framework responsibly, thus we propose a transparent hybrid approach in
decision making with input from both this framework and experienced domain professionals.
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1 General log-likelihood
The general likelihood-based loss hypothesis that accounts for informative censoring is formulated
as:
−`h,Φ(ta, ca, y, δ) = log ph,Φ,ν(TA, CA|X = x) (1)
= log ph,Φ(TA|X = x) + log pν,Φ(CA|X = x) , (2)
where (2) follows from the conditional independence (informative censoring) assumption T ⊥
C|X,A. For some parametric formulations of event ph,Φ(TA|X = x) and censoring pν,Φ(CA|X =
x) time distributions, e.g., exponential, Weibull, log-Normal, etc., then −`h,Φ(ta, ca, y, δ) is the
closed-form log-likelihood, where:
log ph,Φ(TA|X = x) , δ · log fh,Φ(ta|x) + (1− δ) · logSh,Φ(ta|x), (3)
log ph,Φ(CA|X = x) , (1− δ) · log eν,Φ(ca|x) + δ · logGν,Φ(ca|x), (4)
where {Sh,Φ(·), Gν,Φ(·)} and {fh,Φ(·), eν,Φ(·)} are survival and density functions respectively.
2 Metrics
2.1 Estimands of Interest
Several common estimands of interest include [17, 16]:
• Difference in expected lifetime: ITE(x) = ∫ tmax
0
{S1(t|x)− S0(t|x)}dt = E{T1 − T0|X = x}.
• Difference in survival function: ITE(t, x) = S1(t|x)− S0(t|x).
• Hazard ratio: ITE(t, x) = λ1(t|x)/λ0(t|x).
In our experiments, we consider both the hazard ratio and difference in expected lifetime. The
difference of expected lifetime is expressed in terms of both survival functions and expectations:
E[T |X = x] =
∫ ∞
−∞
tf(t|x)dt
=
∫ ∞
0
(1− F (t|x)) dt−
∫ 0
−∞
F (t|x)dt (5)
=
∫ tmax
0
S(t|x)dt , (6)
where (5) follows from standard properties of expectations and (6) from 1 − F (t|x) = S(t|x)
and
∫ 0
−∞ F (t|x)dt = 0. Below we formulate an approach for estimating the individualized and
population hazard ratio.
Preprint. Under review.
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2.2 Nonparametric Hazard Ratio
From standard survival function definitions [10], the relationship between survival and hazard function
is formulated as
λ(t|x) = lim
dt→0
P (t < T < t+ dt|X = x)
P (T > t|X = x)dt = −
d logS(t|x)
dt
=
f(t|x)
S(t|x) . (7)
We propose a new nonparametric hazard ratio, model-free estimator for computing HR(t).
Definition 1 We define the nonparametric marginal Hazard Ratio and its approximation, HˆR(t), as
HR(t) =
λ1(t)
λ0(t)
=
S0(t)
S1(t)
· S
′
1(t)
S′0(t)
, HˆR(t) =
SˆPKM0 (t)
SˆPKM1 (t)
· m1(t)
m0(t)
, (8)
where for HR(t) we leveraged (7) and S′(t) , dS(t)/dt. For the estimator HˆR(t), provided that
S(t) is a monotonically decreasing function, for simplicity, we fit a linear function S(t) = m · t+ c
and set S′(t) ≈ m. Further, we leverage SˆPKM(t) in [4], defined as the model-free population
point-estimate-based nonparametric Kaplan-Meier [9] estimator. We denote J distinct and ordered
observed event times (censored and non-censored) by the set T = {tj |tj > tj−1 > . . . > t0} from
N realizations of Y . Formally, the population survival SˆPKMA (t) is recursively formulated as
SˆPKMA (tj) =
1− ∑n:δn=1 I
(
tj−1 ≤ γ(T (n)A ) < tj
)
N −∑Nn=1 I(γ(T (n)A ) < tj−1)
 SˆPKMA (tj−1) , (9)
where SˆPKMA (t0) = 1, and I(b) represent an indicator function such that I(b) = 1 if b holds or
I(b) = 0 otherwise. Further, γ(·) is a deterministic transformation for summarizing TA, in our
experiments, γ(·) = median(·), computed over samples from ta ∼ ph,Φ(TA|X = x). Note from (9),
we marginalize both factual and counterfactual predictions given covariates x.
A similar formulation for the conditional, individualized HR(t|x), can also be derived, where the
cumulative density FA(t|x) = 1− SA(t|x), is estimated with a Gaussian Kernel Density Estimator
(KDE) [14] on samples from the model, ta ∼ ph,Φ(TA|X = x). Then we have:
HR(t|x) = λ1(t|x)
λ0(t|x) =
S0(t|x)
S1(t|x) ·
S′1(t|x)
S′0(t|x)
, HˆR(t|x) = Sˆ
KDE
0 (t|x)
SˆKDE1 (t|x)
· m1(t|x)
m0(t|x) , (10)
where, S′(t|x) , dS(|t|x)/dt is also approximated with fitting a linear function S(t|x) = m · t+ c,
and setting S′(t|x) ≈ m. Note that for some parametric formulations, HR(t|x), can be readily
evaluated because f(ta|x) and S(ta|x) are available in closed form.
2.3 Factual Metrics
Concordance Index C-Index (also related to receiver operating characteristic) is a widely used
survival ranking metric which naturally handles censoring. It quantifies the consistency between
the order of the predicted times or risk scores relative to ground truth. C-Index is evaluated on
point estimates, we summarize individualized predicted samples from NFR and NFR-INFO, i.e.,
tˆa = median
({ts}200s=1), where ts is a sample from the trained model.
Calibration Slope Calibration quantifies distributional statistical consistency between model pre-
dictions relative to ground truth. We measure population calibration by comparing population survival
curves from model predictions against ground truth according to [4]. We desire a high calibrated
model, with calibration slope of 1, while a slope < 1 and slope > 1 indicates underestimation or
overestimation risk, respectively.
Coefficient of Variation The coefficient of variation (COV) σµ−1, the ratio between standard
deviation and mean, quantifies distribution dispersion. A COV > 1 and < 1 indicates a high or
low variance distribution, in practice, we desire low variance distribution. We use Mean COV
N−1
∑N
i=1 σiµ
−1
i , where for subject i we compute {µi, σi} from samples {ts}200s=1.
2
3 Baselines
Cox proportional hazard (CoxPH) CoxPH assumes a semi-parametric linear model λ(t|a) =
λb(t) exp(aβ) , thus the hazard ratio between treatment and control can be obtained without specify-
ing the baseline hazard λb(t):
HR(t) =
λ(t|a = 1)
λ(t|a = 0) = exp(β) . (11)
A simple logistic model eˆi = σ(xi; η), is used to approximate the unknown propensity score
P (A = 1|X = x). Methods that adjust for selection bias (or confounding) learn β by maximizing a
propensity weighted partial likelihood [13, 2, 12]
L(β) =
∏
i:δi=1
(
exp(aiβ)∑
j:tj≥ti wˆj · exp(ajβ)
)wˆi
. (12)
We consider three normalized weighting schemes for w , namely, (i) inverse probability weighting
(IPW) [8, 3], where IPWi = aieˆi +
1−ai
1−eˆi , (ii) overlapping weights (OW) [6, 11], where OWi =
ai · (1− eˆi) + (1− ai) · eˆi, and (iii) the standard RCT Uniform assumption. Note that this modeling
approach requires fitting over the entire dataset, thus has no inference capability.
Accelerated Failure Time (AFT) We implement IPM regularized neural-based log-Normal and
Weibull AFT baselines. Both approaches have a desirable closed form Sh,Φ(ta|x), thus enabling
maximum likelihood based estimation, where
−LAFTF , E(y,δ,x,a)∼p(y,δ,X,A) [δ · log fh,Φ(ta|x) + (1− δ) · logSh,Φ(ta|x)] . (13)
The log-Normal mean and variance parameters are learned such that, log ta = µh,Φ(h(r, a)) + ,
where  ∼ N (0, σ2h,Φ(h(r, a))) and r = Φ(x). Further, we learn the Weibull scale and shape
parameters, where ta = λh,Φ(h(r, a)) · (− logU)(kh,Φ(h(r,a)))
−1
and U ∼ Uniform(0, 1). We
regularize (13) with the IPM loss, for maximum likelihood optimization.
Semi-supervised regression (SR) To demonstrate the effectiveness of our flow-based uncertainty
estimation approach we contrast NFR with a deterministic accuracy objective from [5], where
ta = h(r, a) and:
LSRF , E(y,δ,x,a)∼p(y,δ,X,A) [δ · (|y − ta|) + (1− δ) · (max(0, y − ta))] , (14)
where (14) is regularized according to the IPM loss.
Survival Bayesian additive regression trees (Surv-BART) Surv-BART [15] is a nonparametric
tree-based approach for estimating individualized survivals Sˆ(t(j)a |X = x) (defined at pre-specified
J time-horizons) from an ensemble of regression trees. Note, Surv-BART does not adjust for both
selection bias and informative censoring. While, we fit two separate models based on factual treatment
and control data, causal metrics are estimated with both factual and counterfactual predictions.
4 Experiments
4.1 Generating ATCG-Synthetic Dataset
The ACTG-SYNTHETIC, is a semi-synthetic dataset based on ACTG covariates [7]. We simulate
potential outcomes according to a Gompertz-Cox distribution [1] with selection bias from a simple
logistic model for P (A = 1|X = x) and AFT-based censoring mechanism. Below is our generative
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Table 1: Performance comparisons on ACTG data, with 95% HR(t) confidence interval. Test set NN
assignment of yCF and δCF yields unbiased ground truth estimator HR(t) = 0.54(0.51,0.61), since
study is a RCT.
Method Causal Factual
HR(t) C-Index (A=0, A=1) Mean COV C-Slope (A=0, A=1)
CoxPH-Uniform 0.49(0.38,0.64) NA NA NA
CoxPH-IPW 0.49(0.36,0.68) NA NA NA
CoxPH-OW 0.49(0.36,0.68) NA NA NA
Surv-BART 3.93(3.93,4.90) (0.665, 0.845) 0.001 (0.394, 0.517)
AFT-Weibull 0.53(0.53,0.53) (0.53,0.351) 3.088 (0.847,0.813)
AFT-log-Normal 3.75(3.75,3.75) (0.717, 0.619) 7.995 (0.847, 0.321)
SR 0.21(0.21,0.28) (0.628, 0.499) 0 (1.388, 0.442)
NFR (proposed) 0.63(0.59,0.68) (0.831, 0.814) 0.132 ( 1.042, 1.129)
NFR-INFO (proposed) 0.6(0.54,0.66) (0.786, 0.822) 0.13 (0.875, 0.938)
scheme:
X = ACTG covariates
P (A = 1|X = x) = 1
b
× (a+ σ (η(AGE− µAGE + CD40− µCD40)))
TA =
1
αA
log
[
1− αA logU
λA exp (xTβA)
]
, U ∼ Uniform(0, 1)
logC ∼ Normal(µc, σ2c )
Y = min(TA, C) , δ = 1 if TA < C, else δ = 0 ,
where {βA, αA, λA, b, a, η, µc, σc} are hyper-parameters and {µAGE, µCD40} are the means for age
and CD40 respectively. This semi-synthetic dataset will made publicly available.
4.2 Quantitative Results
See Table 1 for additional quantitative comparisons on ACTG dataset.
4.3 Qualitative Results
(a) ACTG HR(t) (b) FRAMINGHAM HR(t)
Figure 1: Inferred population HR(t) comparisons on (a) ACTG and (b) FRAMINGHAM datasets.
Figure 1 demonstrates model comparisons across of population hazard, HR(t), on ACTG and FRAM-
INGHAM datasets. Figure 2, summarizes the positive and negative covariate statistics from the isolated
extreme top and bottom quantiles on FRAMINGHAM datasets.
4.4 Architecture of the neural network
We detail the architecture of neural-based methods, namely, baselines (AFT-log-Normal, AFT-
Weibull, SR) and our proposed methods (NFR and NFR-INFO). All methods are trained using one
4
(a) FRAMINGHAM HR(t|x) < 0.024 (b) FRAMINGHAM HR(t|x) > 1.916
Figure 2: Covariate statistics for top (a) and bottom (b) quantiles, of the median log HR(t|x) values
for the test set of FRAMINGHAM.
NVIDIA P100 GPU with 16GB memory. In all experiments we set the minibatch size M = 200,
Adam optimizer with the following hyperparameters: learning rate 3 × 10−4, first moment 0.9,
second moment 0.99, and epsilon 1× 10−8. Further, all network weights are initialed according to
Uniform(−0.01, 0.01). Datasets are split into training, validation and test sets according to 70%,
15% and 15% partitions, respectively, stratified by event and treatment proportions. The validation
set is used for hyperparameter search and early stopping. All hidden units in {hA(·), νA(·)}, are
characterized by Leaky Rectified Linear Unit (ReLU) activation functions, batch normalization and
dropout probability of p = 0.2 on all layers. The output layers of predicted times {TA, CA} have an
additional exponential transformation.
Encoder The encoding function Φ(·) for mapping r = Φ(x) is shared among all the neural based
methods (proposed and baselines) and specified in terms of two-layer MLPs of 100 hidden units.
(a) AFT-log-Normal (b) AFT-Weibull (c) SR
Figure 3: Decoding architecture of baselines.
(a) NFR (b) NFR-INFO
Figure 4: Decoding architecture of proposed methods.
Decoder Figure 3 shows the architectural details of the baselines, where the decoding function
hA(·) is specified in terms of two-layer MLPs of 100 hidden units. Further, the proposed planar
flow based methods shown in Figure 4, are comprised of two-layer MLPS for {hA(·), νA(·)} of
dimensions [100, 200]. Moreover, the hidden layers {h(2)A , ν(2)A }, take as input the concatenated
[h
(1)
A , ˜h] and [ν
(1)
A , ˜ν ] respectively. Finally, we set the planar flow dimensions for both {˜ν , ˜h} to
100.
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